|Table of Contents|

The expression of E-cadherin,Vimentin,and mismatch repair related proteins in gastric cancer tissue and their relationship with patient prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 18
Page:
3420-3427
Research Field:
Publishing date:

Info

Title:
The expression of E-cadherin,Vimentin,and mismatch repair related proteins in gastric cancer tissue and their relationship with patient prognosis
Author(s):
ZHANG Lei1; SUN Xiaona2; ZHANG Li3; GAO Yuanyuan4; SHEN Zhihua5
1.The First Department of General Surgery;2.Pathology Department;3.Ultrasound Department,the Third Hospital of Chengde,Hebei Chengde 067000,China;4.Ultrasound Department,General Hospital of Chengde Iron and Steel Group,Hebei Chengde 067000,China;5.Oncological Pathology Department,Central Hospital of Chengde,Hebei Chengde 067000,China.
Keywords:
gastric cancer; E-cadherin protein; Vimentin protein; dMMR; prognosis model
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.18.016
Abstract:
Objective:To analyze and explore the clinical significance and relationship of E-cadherin,Vimentin and mismatch repair proteins (MMR) and clinical pathological characteristics in patients with GC,using the expression of E-cadherin,Vimentin and MMR proteins observed.Methods:104 patients with complete data who underwent GC operation in Central Hospital of Chengde from May,2020 to December,2020 were enrolled.Immunohistochemical staining was used to observe E-cadherin,Vimentin and MMR proteins,which were divided into positive and negative groups of E-cadherin and Vimentin,as well as dMMR and pMMR groups.Cox proportional risk model was applied to predict the significance of E-cadherin,Vimentin and MMR proteins on overall survival (OS),which divided into high and low risk groups.Kaplan-Meier was performed to analyze the OS of patients with GC.Results:Among 104 cases,the rate of dMMR was 22.12%,the positive expression rates of E-cadherin and Vimentin were 28.85% and 51.92%,respectively.Among them,there were statistically significant differences in Lauren type,pT and pTNM stages,tumor differentiation between dMMR and pMMR groups (P＜0.05).Lauren type,pT and pTNM stages,tumor differentiation,lymphovascular invasion were showed significant differences among positive and negative groups of Vimentin in statistics(P＜0.05).Only pTNM stage was different between E-cadherin-positive group and E-cadherin-negative group (P＜0.05).After follow-up,the median OS time was 19 (15,24) months and the rate of OS was 76.9%.The rates of OS in dMMR,E-cadherin-positive and Vimentin-positive were 83.6%,76.5% and 63.0%,respectively (P＜0.001).The death risk of the patients with high risk was 8.20 times (2.75,24.40) more than those with low risk based on the cutoff value (1.447) of prognostic model,the median survival time of the former (20 months) was obviously worse than that of the latter (30 months),with difference in statistics (P＜0.001).Prognostic model heat map showed that the patients with dMMR had a good prognosis,and the survival advantage was 1.420 times more than that of the patients with pMMR.While there was a worse prognosis in Vimentin-positive patients,with 2.433 times in risk of death worse than that of patients with Vimentin-negative (P＜0.001).The predicted and measured rates of the model were relatively close (P=0.341＞0.05),the AUC value of ROC was 0.88 (0.78~0.97),and the sensitivity and specificity were 83.3% and 57.5%,respectively (P＜0.001),according to calibration curve and ROC analysis,indicating that the model's differentiation and calibration were within the acceptable range.Conclusion:Patients with dMMR have better prognosis,while those with positive of Vimentin have worse prognosis.Based on the expression of MMR,E-cadherin,Vimentin,the establishment of prognostic model has certain clinical significance for the patients with GC.

References:

［1］CHEN Y,TAN S,LI W，et al.Visual analysis of global research on immunotherapy for gastric cancer:A literature mining from 2012 to 2022［J］.Hum Vacc Immunother,2023,19(1):2186684.
［2］PATEL TH,CECCHINI M.Targeted therapies in advanced gastric cancer［J］.Curr Treat Options Oncol,2020,21(9):70.
［3］HAN X,LU H,TANG X,et al.Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene dignatures ［J］.Immun Inflamm Dis,2022,10(1):43-59.
［4］BENCIVENGA M,SIMBOLO M,CIAPARRONE C,et al.Poorly cohesive gastric cancers showing the transcriptomic hallmarks of epithelial-mesenchymal transition behave aggressively ［J］.Ann Surg,2022,276(5):822-829.
［5］XIAO T,JIE Z,ZOU J,et al.Overexpression of SATB1 correlates with epithelial-mesenchymal transition and lymphatic metastasis in gastric cancer ［J］.Ann Diagn Pathol,2022,62:152074.
［6］ZUO X,CAI J,CHEN Z,et al.CircPCSK5 is highly expressed in gastric cancer and promotes cancer cell proliferation,invasion and epithelial-mesenchymal transition［J］.Journal of Southern Medical University,2022,42(10):1440-1451.
［7］PULIGA E,CORSO S,PIETRANTONIO F,et al.Microsatellite instability in gastric cancer:Between lights and shadows ［J］.Cancer Treat Rev,2021,95:102175.
［8］KANG YJ,OHAIRE S,FRANCHINI F,et al.A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR,MSI,high TMB) in different solid tumours ［J］.Sci Rep,2022,12(1):20495.
［9］ZHAO C,FENG Z,HE H,et al.Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray ［J］.PLoS One,2020,15(10):e0238836.
［10］LOPEZ SALA P,LETURIA ETXEBERRIA M,INCHAUSTI IGUINIZ E,et al.Gastric adenocarcinoma:A review of the TNM classification system and ways of spreading ［J］.Radiologia (Engl Ed),2023,65(1):66-80.
［11］YANG RK,CHEN H,ROY-CHOWDHURI S,et al.Clinical testing for mismatch repair in neoplasms using multiple laboratory methods ［J］.Cancers (Basel),2022,14(19):4550.
［12］XIANG R,GE Y,SONG W,et al.Pyroptosis patterns characterized by distinct tumor microenvironment infiltration landscapes in gastric cancer ［J］.Genes (Basel),2021,12(10):1535.
［13］HAO D,HE S,HARADA K,et al.Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma ［J］.Gut,2021,70(11):2055-2065.
［14］TSAI JH,JENG YM,CHEN KH,et al.An integrative morphomolecular classification system of gastric carcinoma with distinct clinical outcomes ［J］.Am J Surg Pathol,2020,44(8):1017-1030.
［15］REITSAM NG,MARKL B,DINTNER S,et al.Concurrent loss of MLH1,PMS2 and MSH6 immunoexpression in digestive system cancers indicating a widespread dysregulation in DNA repair processes ［J］.Front Oncol,2022,12:1019798.
［16］SMYTH EC,WOTHERSPOON A,PECKITT C,et al.Mismatch repair deficiency,microsatellite instability,and survival:An exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial ［J］.JAMA Oncol,2017,3(9):1197-1203.
［17］STOLZE T,FRANKE S,HAYBAECK J,et al.Mismatch repair deficiency,chemotherapy and survival for resectable gastric cancer:an observational study from the German staR cohort and a meta-analysis ［J］.J Cancer Res Clin Oncol,2023,149(3):1007-1017.
［18］COHEN R,TAIEB J,FISKUM J,et al.Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin:An ACCENT pooled analysis of 12 adjuvant trials ［J］.J Clin Oncol,2021,39(6):642-651.
［19］KUBOTA Y,KAWAZOE A,SASAKI A,et al.The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer ［J］.Clin Cancer Res,2020,26(14):3784-3790.
［20］TSAI CY,LIN TA,HUANG SC,et al.Is adjuvant chemotherapy necessary for patients with deficient mismatch repair gastric cancer?-Autophagy inhibition matches the mismatched ［J］.Oncologist,2020,25(7):e1021-e1030.
［21］DONG Z,NI B,YANG L,et al.Efficacy and safety of camrelizumab in combination with docetaxel+S-1 sequenced by camrelizumab+S-1 for stage III (PD-1+/MSI-H/EBV+/dMMR) gastric cancer:Study protocol for a singal-center,prospective,open-label,single-arm trail ［J］.Front Surg,2022,9:917352.
［22］LIN H,WENG J,MEI H,et al.5-Lipoxygenase promotes epithelial-mesenchymal transition through the ERK signaling pathway in gastric cancer ［J］.J Gastroen Hepatol,2021,36(2):455-466.
［23］XIAO T,JIE Z,ZOU J,et al.Overexpression of SATB1 correlates with epithelial-mesenchymal transition and lymphatic metastasis in gastric cancer ［J］.Ann Diagn Pathol,2023,62:152074.
［24］FANG T,ZHANG L,YIN X,et al.The prognostic marker elastin correlates with epithelial-mesenchymal transition and vimentin-positive fibroblasts in gastric cancer ［J］.J Pathol Clin Res,2023,9(1):56-72.
［25］RYU HS,PARK DJ,KIM HH,et al.Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer ［J］.Hum Pathol,2012,43(4):520-528.
［26］GAZZILLO A,POLIDORO MA,SOLDANI C,et al.Relationship between epithelial-to-mesenchymal transition and tumor-associated macrophages in colorectal liver metastases ［J］.Int J Mol Sci,2022,23(24):16197.
［27］MILULA M,NAJJAR S,EL JABBOUR T,et al.Increased cytoplasmic yes-associated protein (YAP) expression in mismatch repair protein-proficient colorectal cancer with high-grade tumor budding and reduced autophagy activity ［J］.Appl Immunohistochem Mol Morphol,2021,29(4):305-312.
［28］MEHDI S,MOHAMMAD RK,AMIR HK,et al.Network-based and machine-learning approaches identify diagnostic and prognostic models for EMT-type gastric tumors［J］.Genes (Basel),2023,14(3):750.
［29］LEE J,CRISTESCU R,KIM KM,et al.Development of mesenchymal subtype gene signature for clinical application in gastric cancer ［J］.Oncotarget,2017,8:66305-66315.

Memo

Memo:
河北省承德市科学技术研究与发展计划（编号：202002A008）
Last Update: 1900-01-01